HIGHLIGHTS
- who: Anagha Deshpande from the Institute of Hematology and Transfusiology (IHT), Poland Wake Forest University, United States have published the article: Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies, in the Journal: (JOURNAL)
- what: This trial compared polatuzumab vedotin to pinatuzumab vedotin - another antibody-drug conjugate targeted at CD22 .
- how: This study also found that cells became re-sensitized to treatment when an IGF1R inhibitor was utilized .
- future: The authors of this study did note that further investigation of this mechanism of resistance is needed .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.